Subclinical atrial fibrillation: Implications of recent trials for guideline updates?

doi:10.4330/wjc.v18.i1.111882

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 1

This Article

(49)

(110)

(0)

(1131)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Cardiol. Jan 26, 2026; 18(1): 111882
Published online Jan 26, 2026. doi: 10.4330/wjc.v18.i1.111882

Full Size Figure Download Figure

Figure 2 The four pivotal direct oral anticoagulant trials in patients with cryptogenic stroke & subclinical atrial fibrillation. The NAVIGATE ESUS & RE-SPECT embolic stroke of unknown source evaluated the role of direct oral anticoagulant therapy in cryptogenic stroke, while NOAH-AFNET-6 & ARTESIA enrolled patients with subclinical atrial fibrillation. ESUS: Embolic stroke of unknown source.

Citation: Pradhan A, Shah S, Vishwakarma P, Singh AK. Subclinical atrial fibrillation: Implications of recent trials for guideline updates? World J Cardiol 2026; 18(1): 111882
URL: https://www.wjgnet.com/1949-8462/full/v18/i1/111882.htm
DOI: https://dx.doi.org/10.4330/wjc.v18.i1.111882

Pradhan A, Shah S, Vishwakarma P, Singh AK. Subclinical atrial fibrillation: Implications of recent trials for guideline updates? World J Cardiol 2026; 18(1): 111882 [PMID: 41607628 DOI: 10.4330/wjc.v18.i1.111882]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.